The focus on how BMI should be used may have overshadowed an equally, if not more important, matter proposed in a new report.

A retrospective study demonstrated slightly elevated baseline fasting plasma glucose levels to be a robust marker of incident diabetes risk, even when those levels fell within the normal range.

American doctors have now discovered the injections put users at 'significantly higher' risk compared to three other common diabetes drugs.